SCHEMBL4160702

SCHEMBL4160702

CC(C)(F)Cc1nc2cccnc2c(N)c1N

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.42
TLR8 Q9NR97 12/20 0.38
LMNA P02545 1/20 0.38
TLR7 Q9NYK1 7/20 0.37
TOP1 P11387 3/20 0.36
HRH4 Q9H3N8 1/20 0.35
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
CASP1 P29466 1/20 0.33
HTT P42858 1/20 0.33
ATM Q13315 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1898669 0.85 PRMT5 (0.42) PRMT5TLR8LMNATLR7HRH4
SCHEMBL5510923 0.78 PRMT5 (0.41) PRMT5TLR8LMNATLR7TOP1
SCHEMBL191231 0.76 PRMT5 (0.44) PRMT5TLR8LMNATLR7HRH4
SCHEMBL2750294 0.73 TLR8 (0.37) PRMT5TLR8LMNATLR7HRH4
SCHEMBL4376577 0.73 EGFR (0.42) PRMT5TOP1HRH4KDM4EALDH1A1
SCHEMBL5794472 0.72 PRMT5 (0.40) PRMT5TLR8LMNATLR7TOP1
SCHEMBL3351060 0.69 TLR8 (0.44) PRMT5TLR8TLR7ALDH1A1HTT
SCHEMBL3354950 0.69 TLR8 (0.38) PRMT5TLR8LMNATLR7HRH4
SCHEMBL6053091 0.69 TLR8 (0.38) PRMT5TLR8LMNATLR7HRH4
SCHEMBL4144691 0.68 IRAK4 (0.37) PRMT5TLR8LMNATLR7HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-8343993-B2 Hydroxyalkyl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-01-01 US disclosed
US-20090253695-A1 Hydroxyalkyl Substituted Imidazonaphthyridines COLEY PHARMACEUTICAL GROUP, INC, (US) 2009-10-08 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed
EP-1851220-A2 HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES 3M Innovative Properties Company (US) 2007-11-07 EP disclosed
EP-1850849-A2 METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON Coley Pharmaceutical Group, Inc. (US) 2007-11-07 EP disclosed
WO-2006091647-A2 METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 WO disclosed
WO-2006091568-A2 HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon IFNG, IFNAR1, EIF2AK2 PRMT5 1751/4885TLR8 494/4885LMNA 4342/4885
US-20090253695-A1 Hydroxyalkyl Substituted Imidazonaphthyridines IFNG, IFNAR1, IRF3 PRMT5 2984/4885TLR8 187/4885LMNA 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.